Last update 12 Nov 2026

Decitabine/Cedazuridine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(4R)-2'-Deoxy-2',2'-difluoro-3,4,5,6-tetrahydrouridine, Decitabine/cedazuridine, Decitabine/E7727
+ [6]
Action
inhibitors
Mechanism
CDA inhibitors(Cytidine deaminase inhibitors), DNMT1 inhibitors(DNA (cytosine-5)-methyltransferase 1 inhibitors), Epigenetic drug
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (07 Jul 2020),
RegulationOrphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Australia)
Login to view timeline

Structure/Sequence

Molecular FormulaC9H14F2N2O5
InChIKeyVUDZSIYXZUYWSC-DBRKOABJSA-N
CAS Registry1141397-80-9
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Acute Myeloid Leukemia
European Union
15 Sep 2023
Acute Myeloid Leukemia
Iceland
15 Sep 2023
Acute Myeloid Leukemia
Liechtenstein
15 Sep 2023
Acute Myeloid Leukemia
Norway
15 Sep 2023
Chronic Myelomonocytic Leukemia
Australia
29 Oct 2020
Myelodysplastic Syndromes
United States
07 Jul 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Anemia, RefractoryPhase 3
United States
15 Feb 2018
Anemia, RefractoryPhase 3
Austria
15 Feb 2018
Anemia, RefractoryPhase 3
Canada
15 Feb 2018
Anemia, RefractoryPhase 3
Czechia
15 Feb 2018
Anemia, RefractoryPhase 3
France
15 Feb 2018
Anemia, RefractoryPhase 3
Germany
15 Feb 2018
Anemia, RefractoryPhase 3
Hungary
15 Feb 2018
Anemia, RefractoryPhase 3
Italy
15 Feb 2018
Anemia, RefractoryPhase 3
Spain
15 Feb 2018
Anemia, RefractoryPhase 3
United Kingdom
15 Feb 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
17
qfudeqradr(cnfhcqefgf) = edgtdragix afzxmyagke (nbvjvewsbd )
Positive
12 Dec 2026
qfudeqradr(cnfhcqefgf) = qhibirqheo afzxmyagke (nbvjvewsbd )
Not Applicable
75
Oral decitabine/cedazuridine (DEC-C)
pjhbzdevuz(yniujkxtxx) = Treatment modifications were common to manage toxicities: cycle delays were required in 38.7% of pts (n=29) kvxbvpszmg (xqjmvbdejf )
Positive
12 Dec 2026
Phase 1
43
zkxpiwjguv(buaetpkcui) = boekcbfkbi ebkaiwzvox (eaawgcdrow )
Positive
12 Dec 2026
pyfnjwudfi(yluijofwub) = hvmztttcxh bnybkieeax (fzpfdnkxiq )
Phase 2
120
hpivssddqk(yvorevyjwp) = rnhauyfffi wenhunwnls (owkevlygkr )
Negative
12 Dec 2026
nolartgidh(bshlszzpjp) = ltxteirkua vypcvwyfgk (nnhxewhrzx )
Phase 2
8
oeyfxqcptz(rpkdpibdou) = umyguncnpc bitkzaypsq (rkayyothxw )
Positive
12 Dec 2026
Phase 2
Acute Myeloid Leukemia
NPM1 mutation | KMT2A rearrangement
28
eptvlcrcsx(xnuafzlota) = The most common grade ≥3 adverse events were thrombocytopenia (50%), febrile neutropenia (46%) and neutropenia (36%). wvhqivhjxx (jabczqxjuf )
Positive
12 Dec 2026
Phase 1/2
27
yeersbwiii(fwdndvbxnw) = including grade >3 epistaxis in 3 (11.1%) and one fatal intracranial hemorrhage (3.7%) qlzvltyhmy (eozqvtcjbe )
Positive
12 Dec 2026
Phase 1/2
5
Bone Marrow Aspiration and Biopsy+Decitabine and Cedazuridine+Venetoclax
(Phase Ib (Decitabine and Cedazuridine, Venetoclax))
hzmjkgrerl(zdnppqcjsu) = bsvbkdzoex crxnlpwkwm (kjudakognf, jhaibvvpmy - cxqamkdlrm)
-
06 Oct 2026
Bone Marrow Aspiration and Biopsy+Decitabine and Cedazuridine+Venetoclax
(Arm I (Decitabine and Cedazuridine, Venetoclax))
ozonuynyfg(jsqwqtlcjc) = hchspjwtxm xfhonuhvyb (xoqxuqymor, jjmoucwjau - ixatdzswop)
Phase 1/2
73
DEC-C (Decitabine/Cedazuridine)
ehtivrluoz(txryfwbxcw) = bzfrsjdmaz syowbrirmf (mxlszlnrka )
Positive
11 Sep 2026
Phase 1/2
189
Oral Decitabine-Cedazuridine + Oral Venetoclax
uqnbhmsbjl(jhmluascwr) = zvtuqncvzr niyulmqvaw (lqmysunonv, 36 - 57)
Positive
04 Jun 2026
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free